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requirement in France; continuous monitoring will be needed to better understand 
positive and negative drivers of decisions.
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Objectives: This study was designed to understand consumer interest in a mobile 
application designed to allow individuals to view their personal health record on a 
mobile device, and to share their health records with someone else if they choose. 
As a secondary objective, this study evaluated the likelihood of consumers to use 
the device based on the varying risk of a leak of their identifiable information (risk 
tolerance). MethOds: A representative (U.S.) sample of 1,000 adults completed 
an online survey about their interest in an EHR mobile application. Interest in the 
application was elucidating using a 7-point Likert scale and a standard gamble 
(SG) exercise. Results: Prior to any indication of a potential privacy risk, 31% of 
consumers indicate they would be very likely to download an EHR mobile applica-
tion (rated 6 or 7 on 7-point Likert scale; 4.0 mean). Nearly half (44%) of those who 
do not expect to use the app indicate they have privacy concerns. Based on the SG, 
only 50% report they would download the mobile application if there was a 95% 
chance their data was completely secure. Expected use of the application declines 
rapidly; 39% would use it if there was a 90% chance their data was completely 
secure and 31% would use it if there was an 85% chance their data was completely 
secure. Only 3% are still interested in the application with only a 5% chance their 
data was completely secure. cOnclusiOns: There is a sizeable market for EHR 
mobile applications. Up to half of consumers report interest in using an EHR mobile 
application; and yet, there are important data concerns. Particularly given large-
scale data breaches of large organizations, it will be critical for developers to quell 
fears of potential users of a data leak.
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Objectives: Since January 2011, the German G-BA has evaluated new drugs on 
their degree of added benefit versus a comparator therapy. We used disease-specific 
Disability Adjusted Life Years (DALYs), reported by the World Health Organization 
(WHO) as the sum of Years of Life Lost from mortality (YLL) plus Years Lost due to 
Disability (YLD), to help explain G-BA benefit assessment decisions. MethOds: 
EMA-approved drugs (January 2010-June 2015) were identified from European Public 
Assessment Reports (EPARs) and cross-referenced with the G-BA website to create 
an analysis set of drugs that have received benefit assessment ratings. Drugs with 
EMA orphan-drug designation were excluded. We defined Added Benefit (AB) as 
drugs that received G-BA ratings of “considerable”, “low”, or “unquantifiable” ben-
efit in any patient subgroup, and No Added Benefit (NAB) as drugs only receiving 
ratings of “no additional benefit” and “inferior”. Using WHO-reported German 2012 
DALYs, proportions of YLLs and YLDs for each drug’s lead indication were calculated: 
Drugs for diseases in which YLLs > 75% of the DALY were defined as High Mortality 
Drugs (HMD); drugs for all other diseases were Low Mortality Drugs (LMD). We then 
predicted the odds of receiving AB versus NAB based on this new metric. SPSS was 
used to perform Fisher’s exact test and to generate Odds Ratios (OR). Sensitivity 
analyses were performed on the %YLL threshold definition. Results: From 373 
EPARs, we identified 73 non-orphan drugs receiving G-BA benefit assessment rat-
ings, 58 of which had matched DALY data for the lead indication. Of these 58 drugs, 
35 were indicated for HMDs while 23 had LMD indications. 30 of 35 (86%) HMDs 
received an AB rating while only 4 of 23 (17%) LMDs received an AB rating (p< 0.001, 
OR: 28.6). cOnclusiOns: Our analysis suggests that in Germany there may be a 
demonstrated and predictable bias for drugs for fatal diseases.
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Objectives: To assess the progress of a large group of innovative drugs evaluated 
recently under the HTA system introduced in Romania in 2014, which is the mecha-
nism now used to reach decisions on which new medicines are included on the 
reimbursement list. MethOds: A systematic study of the HTA decisions already 
taken by the department for health technology assessment of the Romanian drug 
agency was undertaken, to ascertain the number of medicines / indications approved 
for unconditional reimbursement (not requiring cost-volume contracts), conditional 
reimbursement (requiring cost-volume contracts) and those not qualifying for reim-
bursement. Patterns were sought and identified among those drugs / indications 
which are awarded higher and lower points scores. Results: Of the 144 HTA deci-
sions, considering only originator medicines and their indications, there have been 23 
recommendations for unconditional reimbursement, 51 recommendations for condi-
tional reimbursement, and 70 recommendations for exclusion from reimbursement. 
Among the therapeutic areas and drug types in which unconditional reimbursement 
decisions are frequent are new oral anticoagulant drugs and type-2 diabetes drugs. 
Many older originator medicines have tended to receive lower points scores, not quali-
fying for reimbursement. cOnclusiOns: The HTA points system in Romania is in its 
early stages but already some patterns are emerging from the combination of criteria 
used to accumulate points – including decisions by western European HTA bodies, 
the number of EU member states in which a drug is reimbursed, and the impact on 
the budget of the Romanian health insurer. With major legislative transformations 
underway in Romania’s pharmaceutical pricing and reimbursement system, the real 
made available to patients. The objective of this abstract is to highlight the difference 
of data requirements between the EMA and some of the main HTA bodies, and the 
subsequent outcomes in terms of access and reimbursement decisions. MethOds: 
The list of medicines under CA status was downloaded on March 16th 2015 from the 
EMA website.2 For each medicine, advice from the National Institute for Health and 
Care Excellence (NICE), Scottish Medicines Consortium (SMC), National Authority 
for Health (HAS) and Federal Joint Committee (GBA) was taken from the agencies’ 
websites.3 The HTA outcomes were measured from final recommendation in the 
UK, the medical benefit (SMR) and improvement in medical benefit (ASMR) scores 
in France and the level of additional benefit in Germany. Medicines approved 
after March 2014 (n = 3) and vaccines (n = 2) were excluded. Results: 77% of the 
selected medicines had at least one unfavourable HTA outcome (defined as no or 
restricted recommendation in the UK, SMR lower than substantial and/or ASMR V 
in France, no or unquantifiable additional benefit in Germany). 50% had a majority 
of unfavourable HTA outcomes. cOnclusiOns: Although the EMA seems to have 
accelerated patient access to selected medicines, it does not actually translate into 
patient accessibility as regulators and payers have a different perception on the 
benefits these medicines offer. Greater alignment between regulators and payers is 
needed for patients. 1Article 14(7) of Regulation (EC) No 726/2004; 2http://www.ema.
europa.eu/ema/; 3http://www.has-sante.fr/portail/jcms/r_1500918/en/les-avis-sur-
les-medicaments, http://www.english.g-ba.de/, https://www.nice.org.uk/, https://
www.scottishmedicines.org.uk/Home
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Objectives: Hospitals need a formalized system to introduce new health tech-
nologies. Hospital-based HTA (HB-HTA) units can provide relevant and timely 
information to decision makers. However, to date no comprehensive body of 
knowledge of current practices and tools exists to guide how to set up these units 
in hospitals. AdHopHTA, a European research project funded by the FP7, aims to 
gather information and knowledge and develop these tools. Therefore, our objec-
tives are to present the handbook and web-based toolkit for HB-HTA developed 
by the AdHopHTA project, which aims to guide and facilitate the setting-up and 
the daily work (e.g. assessments) of an HB-HTA unit. MethOds: AdHopHTA has 
used a multi-method approach to develop the content of the handbook and toolkit 
including 6 literature reviews, 107 face-to-face surveys, 40 case studies, 1 large-
scale survey, 1 focus group, 1 Delphi process, 1 validation workshop and several 
Steering and Advisory Committee meetings. In total 375 people from 20 differ-
ent countries have provided their input. Results: The handbook presents the 
informational needs and organizational models of HB-HTA units in Europe. It also 
describes the positive impact of HB-HTA in the adoption of new health technolo-
gies in hospitals and how to create a comprehensive HTA ecosystem through the 
interaction between national or regional HTA organizations and HB-HTA units. 15 
guiding principles for good practices in HB-HTA are also presented using current 
examples from existing HB-HTA units. The Toolkit is built based on these guiding 
principles. It consists of practical guidance grouped into four dimensions (the 
assessment process; leadership, strategy and partnerships; resources and and 
impact). It includes proposed solutions to potential problems as well as specific 
tools (e.g. AdHopHTA mini-HTA template) for each dimension. cOnclusiOns: 
The AdHopHTA Handbook and Toolkit are support instruments for designing, 
setting-up and running HB-HTA units.
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Objectives: The Commission for Economic Evaluations and Public Health 
(Commission Evaluation Economique et de Santé Publique, (CEESP)) has been con-
ducting health economic evaluations since 2008. Due to continued economic pressure, 
as of October 2013, manufacturers are required to submit an economic evaluation to 
the CEESP under certain conditions, in addition to the Commission de Transparence’s 
existing clinical assessment. The objective of this analysis was to gain a better under-
standing of the drivers of positive and negative CEESP decisions. MethOds: All publi-
cally available CEESP decisions were retrieved from the agency’s website in April 2015. 
The CEESP evaluates submissions against the HAS’ pharmacoeconomic guidelines, in 
which areas of weakness are identified through a system of “reserves” rather than a 
strict ICER threshold. Data was extracted to determine the number of and rationale 
for minor, important, and major reserves awarded by CEESP to the manufacturer’s 
submission, as well as accepted incremental cost-effectiveness ratios. Results: 
According to HAS’s methodological guide for economic evaluations, cost-effectiveness 
should be considered alongside clinical efficacy. At the time of analysis, four CEEPS 
appraisals were publically available. 50% of submissions had ICERs above 100,000 EUR 
per QALY gained, and based on findings to date, no firm ICER threshold was apparent. 
50% of submissions were found to have minor, important, as well as major reserves. 
Our analysis revealed 5 key factors to improve the chance of a positive CEESP review: 
(1) A clearly presented analysis with a validated model structure; (2) a submission 
that satisfies the HAS guidelines; (3) a proper justification of all model inputs and 
assumptions; (4) an appropriate comparator; (5) a consideration of the “national fac-
tor”. cOnclusiOns: CEESP appraisal has only recently emerged as a market access 
